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Previously, we described clinical outcomes from the EAP cohort, which provided IFN-free, DAA therapy to >800 HCV-infected patients with decompensated liver disease [3, 4] ; all patients received sofosbuvir±ribavirin (SOF±RBV) combined with either ledipasvir (LDV) or daclatasvir (DCV). Among the Gt1-infected group, 28 patients did not achieve a SVR. From next generation sequence (NGS) analysis, 3 of these patients, designated as Gt1-or Gt1a-infected by the clinical sites, were infected with Gt1l. All 3 patients originated from Nigeria. The patients were retreated with DAAs for a further 24 weeks but again relapsed after therapy. In two Gt1l-infected patients (P1 and P3) where pre-and post-treatment samples were available, there were no sequence changes in either NS5A or NS5B. By contrast, NS5A RASs emerged in Gt1a-infected patients between pre-and post-treatment. For the 3 rd Gt1l-infected patient, NGS data was only available at pre-treatment.
Typically, RAS in NS5A are located at positions 24, 28, 30, 31 and 93 as well as residue 58
(for Gt1a) [1] . However, these positions are polymorphic among HCV genotypes/subtypes.
The Gt1l sequences in patients P1 and P3 between residues 28-31 were identical (MPRM; Table   1 ). Thus, at pre-treatment, both patients contained two documented RAS (Q30R+L31M). The rd gt1l-infected patient, P2, had one RAS (L31M). In a recent report, introducing Q30R+L31M into a Gt1a replicon confers high in vitro resistance for LDV and DCV (>23,400 and >4,452 increased EC50 values, respectively); for Velpatasvir, there is a 198-fold rise in EC50 for these substitutions [5] . In the context of Gt1a, L31M also increases EC50 values for these DAAs but to a lesser extent compared to Q30R+L31M.
In the EAP cohort, there were also one non-responder and 3 responder-relapsers in the Gt4-infected group. From NGS analysis, the non-responder (P4) and one of the three responderrelapsers were infected with Gt4r (P5; Table 1 ); both patients originated from Somalia. The remaining responder-relapsers were Gt4d-infected. Similar to Gt1l-infected patients P1 and P3, no amino acid alterations were detected in NS5A between pre-and post-treatment for the Gt4r non-responder. The sequence between NS5A residues 28-32 in this patient was identical to that for patients P1 and P3 and thus contained a Q30R+L31M RAS doublet. However, a T282 RAS in NS5B, which is associated with SOF resistance [6] , emerged in 100% of sequences at 1 week post-therapy ( Figure 1 ). T282 remained dominant at week 5 posttreatment but at 49 weeks, T282 was not detected and all sequences encoded S282. A similar pattern of emergence and loss of T282 after failed SOF treatment has been reported in a Gt2b-infected patient [7] . The GT4r responder-relapser (P5) had a single NS5A RAS at pretreatment (Q30R) and a further Y93H RAS emerged upon relapse. No amino acid changes were observed in NS5B.
From the limited Gt1l sequences available (n=3), both double (Q30R+L31M) and single RAS (L31M) are present in published strains [8] . Combined with our data, NS5A position 30 is apparently polymorphic in Gt1l and thereby generates strains with double and single RAS, which could increase NS5A DAA resistance. As with Gt1l, there is a paucity of Gt4r sequence data. However, in a recently reported Gt4 cohort (n=44), Gt4r was detected in three subjects, two of whom did not achieve SVR [9] . The non-SVR Gt4r subjects had baseline RAS (M28M/V+Q30R+L31M), which remained the dominant sequences post-treatment. Moreover, a S282T mutation in NS5B emerged at post-treatment for one Gt4r patient. These data complement our findings and, given that the SOF-resistant S282T variant has emerged in 2/4
Gt4r-infected patients who did not achieve SVR, this substitution may arise with higher frequency in rare subtypes such as Gt4r.
We conclude that certain Gt1l and Gt4r strains contain naturally occurring polymorphisms, which could contribute to resistance to NS5A inhibitors in patients with advanced liver disease.
Since decompensated cirrhosis can lead to reduced response to DAAs [10] , it is unclear whether extended duration of initial therapy might be advantageous in such patients nor whether patients with less liver damage would respond differently. Nevertheless, with the growing availability of DAAs, it is important that recommendations and guidance reflect the Further studies investigating DAA efficacy in these and other strains found in LMICs in cirrhotic and non-cirrhotic patients are required. 
